Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer (NeoEribulin)

This study has been completed.
Eisai Inc.
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group Identifier:
First received: August 9, 2012
Last updated: August 5, 2015
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)